Twist Bioscience Corporation - Common Stock (TWST)

Twist Bioscience Corporation hiked its fiscal year 2026 revenue guidance on the heels of a first quarter earnings report that beat Wall Street estimates.

Twist Bioscience Q1 2026 Earnings Call Transcript

Twist Bioscience reports mixed Q4 earnings with a loss of 45 cents, sales of $99.01 million beating consensus.

Twist Bioscience Q4 2025 earnings miss analyst estimates on revenue and EPS, triggering a sharp pre-market stock decline.

Cathie Wood, CEO of Ark Invest, believes healthcare is the most profound application of AI and Wall Street is overlooking its potential.

Cathie Wood-led Ark Invest executed a significant trade in Block Inc. (NYSE:XYZ) on Tuesday.

Twist Bioscience beat Q3 revenue estimates, improved gross margins, and narrowed its full-year outlook while forecasting EBITDA breakeven fiscal 2026.

Twist Bioscience reported mixed Q3 2025 results, missing revenue estimates at $96.06M but beating EPS at -$0.47. Shares fell 5% pre-market as investors focused on the sales shortfall.

Cathie Wood-led Ark Invest made notable trades on Friday, including selling shares in Coinbase and Roblox.

Cathie Wood underscored the application of AI in the healthcare sector by sharing new research by Mass General Brigham.

Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space.